ERBB2 and gastric cancer: When analyzing the large group of gastric cancer patients separately though (n=274), presence of any Her2 immunoreactivity (score 1+, 2+ and 3+) emerged as an independent prognostic factor for overall survival (p=0.014) besides pT category, pN category and distant metastases (Table 6).